Axplora, a German company specialising in API small molecule and ADC manufacturing, is to invest €50 million into its site in Mourenx, France.

The site in Mourenx specialises in API industrial chemistry and chromatography and drug substances for FDA- approved biologics, whilst the investment is intended to further its capabilities in the field. Development at the site is to begin immediately and the first supplies for GLP-1 therapies are expected by 2026. This is expected to bolster Axplora’s position as a supplier of treatments for cardiovascular and metabolic diseases.